← Product Code [OKO](/submissions/SU/subpart-e%E2%80%94surgical-devices/OKO) · K111006 # CI-SNAP WOUND CARE SYSTEM (K111006) _Spiracur, Inc. · OKO · Jul 21, 2011 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OKO/K111006 ## Device Facts - **Applicant:** Spiracur, Inc. - **Product Code:** [OKO](/submissions/SU/subpart-e%E2%80%94surgical-devices/OKO.md) - **Decision Date:** Jul 21, 2011 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4683 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Indications for Use The CI-SNaP™ Wound Care System is indicated for patients who would benefit from a suction device, particularly as the device may promote wound healing through the removal of small amounts of exudates from surgical incisions that continue to drain following sutured or stapled closure. ## Device Story Non-powered, portable, single-use suction device for negative pressure wound therapy (NPWT). Uses dedicated constant-force springs to mechanically generate negative pressure gradient; removes wound exudate, irrigation fluids, and infectious materials. Used in conjunction with CI-SNaP Dressing Kit. Designed for surgical incisions with continued drainage post-closure. Operated by clinicians in operating room or clinical settings. Provides active wound treatment to promote healing. Device modifications from predicate include outer housing changes, receptacle capacity adjustments, activation/deactivation steps, and addition of attachment clip. Cartridge provided terminally sterile. ## Clinical Evidence Bench testing only. Evaluated via design verification tests to confirm delivery of negative pressure wound therapy and biocompatibility. ## Technological Characteristics Non-powered suction apparatus; constant-force spring mechanism; single-use; portable; terminally sterile cartridge; mechanical energy source. ## Regulatory Identification A non-powered suction apparatus device intended for negative pressure wound therapy is a device that is indicated for wound management via application of negative pressure to the wound for removal of fluids, including wound exudate, irrigation fluids, and infectious materials. It is further indicated for management of wounds, burns, flaps, and grafts. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Non-powered Suction Apparatus Device Intended for Negative Pressure Wound Therapy (NPWT).” See § 878.1(e) for the availability of this guidance document. ## Predicate Devices - SNaP™ Wound Care System ([K081406](/device/K081406.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Spiracur Inc. # SECTION 6 510(k) SUMMARY CI-SNaP™ WOUND CARE SYSTEM 510(k) PREMARKET NOTIFICATION # 510(k) Notification K111006 JUL 2 1 2011 # GENERAL INFORMATION #### Applicant: Spiracur Inc. 1180 Bordeaux Drive Sunnyvale, CA 94089 U.S.A. Phone: 408-701-5300 Fax: 408-701-5301 # Contact Person: Sarah L. Canio Experien Group, LLC 155-A Moffett Park Drive, Suite 210 Sunnyvale, CA 94089-1330 U.S.A. Phone: 408-400-0856 Fax: 408-400-0865 Email: sarah@experiengroup.com # Date Prepared: July 6, 2011 #### Classification: 21 CFR§878.4683, Class II #### Product Code: ОКО # Trade Name: CI-SNaP™ Wound Care System #### Generic/Common Name: Non-powered suction apparatus device intended for negative pressure wound therapy # Predicate Device: SNaP™ Wound Care System (K081406) {1}------------------------------------------------ CI-SNaP™ WOUND CARE SYSTEM 510(k) PREMARKET NOTIFICATION #### Spiracur Inc. #### SECTION 6 510(k) SUMMARY #### Intended Use The CI-SNaP™ Wound Care System is indicated for patients who would benefit from a suction device, particularly as the device may promote wound healing through the removal of small amounts of exudates from surgical incisions that continue to drain following sutured or stapled closure. # Product Description The CI-SNaP Wound Care System is a non-powered, portable, single-use suction device intended for wound management via application of negative pressure to the wound for removal of fluids, including exudate, irrigation fluids and infectious materials. The CI-SNaP Wound Care System is designed to provide active wound treatment to help promote healing in surgical incisions that continue to drain following sutured or stapled closure. The CI-SNaP Wound Care System utilizes dedicated constant-force springs to mechanically generate the negative pressure gradient. The CI-SNaP™ Wound Care System is used in conjunction with the CI-SNaP™ Dressing Kit. # Substantial Equivalence The SNaP® System and the CI-SNaP Wound Care System are both non-powered, portable, single-use suction devices intended for wound management via application of negative pressure to the wound for removal of fluids, including wound exudate, irrigation fluids and infectious materials. Both systems utilize dedicated constant-force springs to mechanically generate the negative pressure gradient. The minor design modifications implemented to develop the CI-SNaP System involve changes to the outer housing and receptacle capacity of the SNaP Cartridge, changes to the activation and deactivation steps, and inclusion of an attachment clip to the CI-SNaP. Additionally, the CI-SNaP Cartridge is provided terminally sterile to enable use of the CI-SNaP System in the operating room suite for the patients with surgically closed incisions. Any differences in the technological characteristics between the devices do not raise any new issues of safety or effectiveness. Therefore, the Cl-SNaP Wound Care System is substantially equivalent to the cleared predicate device (K081406). #### Testing in Support of Substantial Equivalence Determination The CI-SNaP Wound Care System and its components were evaluated under design verification tests to assure conformance to design specifications. The nonclinical tests include: - . Bench testing conducted on the CI-SNaP Wound Care System to assess the ability to deliver negative pressure wound therapy - Biocompatibility testing . #### Summary The CI-SNaP Wound Care System is substantially equivalent to the predicate device. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized eagle with three lines representing its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Spiracur % Experien Group, LLC Ms. Sarah Canio 155-A Moffett Park Drive, Suite 210 Sunnyvale, California 94089 JUL 2 1 2011 Re: K111006 Trade/Device Name: CI-SNaP™ Wound Care System Regulation Number: 21 CFR 878.4683 Regulation Name: Non-powered suction apparatus device intended for NPWT Regulatory Class: II Product Code: QKO Dated: July 11, 2011 Received: July 13, 2011 Dear Ms. Canio: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 {3}------------------------------------------------ Page 2 - Ms. Jane Weber CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115800.html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR, Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll the (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely vaurs. For Dick Dr. Dr. eln Dr. Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # SECTION 5 INDICATIONS FOR USE STATEMENT 510(k) Number (if known): K111006 Device Name: CI-SNaP™ Wound Care System #### Indications For Use: The CI-SNaP™ Wound Care System is indicated for patients who would benefit from a suction device, particularly as the device may promote wound healing through the removal of small amounts of exudates from surgical incisions that continue to drain following sutured or stapled closure. Prescription Use X (21 CFR Part 801 Subpart D) And/Or Over the Counter Use (21 CFR Part 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Daniel Krone for NSM Sign Off (Division Sign-Off) Division of Surgical, Orthopedic, Division of Surgices Division of Surges and Restorative Devices 510(k) Number K111006 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OKO/K111006](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/OKO/K111006) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com